March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis
January 15th 2018Here, in Part 1, we will provide an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation. We will also review the current prognostication systems for primary CNS lymphoma.
Electric Fields Therapy Improved Survival for Glioblastoma
December 21st 2017The addition of tumor-treating fields to maintenance temozolomide chemotherapy significantly delayed progression and improved overall survival in patients with glioblastoma who had received standard radiochemotherapy compared with maintenance temozolomide alone.
Brain Mets Can Acquire HER2-Positivity in HER2-Negative Breast Cancer Patients
January 11th 2017Brain metastases from primary breast cancer tumors often acquire clinically actionable genetic alterations, according to a small study. About one fifth of ERBB2/HER2-negative cases switched to HER2-positivity in the brain metastases.
New Agent May Help Combat Glioma Tumors
December 21st 2016Researchers are reporting in the journal Cancer Research that they have identified a biomarker enzyme associated with aggressive glioma brain tumors. In addition, they have demonstrated potent efficacy in a mouse model of glioma for a small molecule inhibitor they recently developed.
A 22-year-old college student with primary amenorrhea due to Müllerian agenesis presented with a headache, dysarthria, nausea, vomiting, and left upper extremity weakness. MRI of the brain showed numerous intracranial lesions.
Researchers Close in on an Epigenetic Mechanism for Carcinogenesis
November 28th 2016Epigenetic lesions, and not just genetic mutations, can cause brain cancer, and one important implication of that observation is that precision-medicine genetic and genomic tools will miss epigenetic lesions that may drive tumor growth or drug resistance.
‘Major Changes’ in New 2016 WHO CNS Tumors Classification
November 21st 2016Four years in the making, the new 2016 World Health Organization Classification of Tumors of the Central Nervous System includes new genetically identified entities and variants, allowing more diagnostic precision, and a new “layered” approach to diagnosis.
Investigating Burnout and Career Satisfaction Among Neuro-Oncologists
November 20th 2016Caring for patients with brain tumors can have marked effects on the well-being of oncology clinicians, frequently leading to burnout, and authors of an ongoing survey study aim to get a clearer picture of those impacts.